Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. will participate in CPHI Japan 2026 in Tokyo, Japan, from April 21 to 23, 2026, at Booth 1C-08.
As a professional service provider deeply engaged in high-end active pharmaceutical ingredients (APIs) and CDMO solutions, we sincerely invite colleagues and partners from the global pharmaceutical industry to visit our booth. We look forward to gathering at this premier industry event, exchanging cutting-edge technologies, precisely matching cooperation needs, and jointly exploring new opportunities in the global pharmaceutical market.
01 Exhibition Overview
CPHI Japan 2026
Dates: April 21 (Tue) – 23 (Thu), 2026
Venue: Tokyo Big Sight, Tokyo, Japan
Organizer: Informa Markets
Scale: Bringing together over 850 exhibitors from around 30 countries and regions, attracting more than 35,000 professional visitors, with an exhibition area of approximately 26,000 square meters.
As one of the most influential professional exhibitions for pharmaceutical ingredients and technologies in Asia, CPHI Japan serves as a vital platform for connecting Japan’s and the global pharmaceutical industry chains, gaining insights into industry trends, and expanding international cooperation.
02 Exhibition Scope
The exhibition covers the entire pharmaceutical industry chain, with key zones including:
-
Ingredients Zone: Active pharmaceutical ingredients (APIs), pharmaceutical intermediates, excipients
-
Outsourcing Services Zone: R&D, production and registration CDMO, CRO, CMO
-
Equipment & Instrument Zone: Laboratory equipment, production equipment, testing instruments
-
Biopharmaceuticals Zone: Biologics R&D, production, testing and related services
-
Formulation & Packaging Zone: Formulation technologies, drug delivery systems, pharmaceutical packaging materials
-
03 About Us
Founded in 2014 and invested by Shandong Chenghui Pharmaceutical Group, Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is located in a provincial-level chemical industrial park in Dezhou, Shandong Province, covering an area of 178 mu.
The company specializes in the R&D and production of high-end APIs, in compliance with international certification standards including GMP, CGMP and CEP.
Core Products
APIs for local anesthesia, antiviral, cardiovascular & cerebrovascular, anti-tumor, digestive tract and diabetes therapies, as well as veterinary drugs, nutritional health products, and customized CDMO services.
Production Capacity
Equipped with multiple production workshops and GMP production lines, with an annual capacity of thousands of tons. Capable of handling complex reactions such as catalytic hydrogenation, ultra-low temperature reactions and microchannel reactions. Supported by a full set of high-end analytical instruments and a professional quality control team.
Market Presence
Products are exported to more than 60 countries and regions. The company enjoys strong industrial competitiveness in antiviral and perioperative APIs.
Corporate Philosophy
Integrity First, Open Cooperation, Innovation-Driven
Committed to becoming a globally trusted partner for pharmaceutical raw materials and customized services.
04 Invitation
Join us from April 21 to 23, 2026, at
Booth 1C-08, Tokyo Big Sight.
Chenghui Shuangda Pharmaceutical looks forward to face-to-face discussions with you for win-win cooperation and shared development.
To schedule a meeting in advance, please contact us:
-
Tel: +86-531-58897029 / 7070
-
Email: lily.yue@chsdpharma.com | market@chsdpharma.com
-
Website: www.chsdpharma.com
